These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 19954816)

  • 1. PBK/TOPK in the differential diagnosis of cholangiocarcinoma from hepatocellular carcinoma and its involvement in prognosis of human cholangiocarcinoma.
    He F; Yan Q; Fan L; Liu Y; Cui J; Wang J; Wang L; Wang Y; Wang Z; Guo Y; Huang G
    Hum Pathol; 2010 Mar; 41(3):415-24. PubMed ID: 19954816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium iodide symporter is expressed at the preneoplastic stages of liver carcinogenesis and in human cholangiocarcinoma.
    Liu B; Hervé J; Bioulac-Sage P; Valogne Y; Roux J; Yilmaz F; Boisgard R; Guettier C; Calès P; Tavitian B; Samuel D; Clerc J; Bréchot C; Faivre J
    Gastroenterology; 2007 Apr; 132(4):1495-503. PubMed ID: 17408651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21.
    Hu F; Gartenhaus RB; Eichberg D; Liu Z; Fang HB; Rapoport AP
    Oncogene; 2010 Oct; 29(40):5464-74. PubMed ID: 20622899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer.
    Park JH; Lin ML; Nishidate T; Nakamura Y; Katagiri T
    Cancer Res; 2006 Sep; 66(18):9186-95. PubMed ID: 16982762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PBK/TOPK promotes tumour cell proliferation through p38 MAPK activity and regulation of the DNA damage response.
    Ayllón V; O'connor R
    Oncogene; 2007 May; 26(24):3451-61. PubMed ID: 17160018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased expression of XPO4 is associated with poor prognosis in hepatocellular carcinoma.
    Liang XT; Pan K; Chen MS; Li JJ; Wang H; Zhao JJ; Sun JC; Chen YB; Ma HQ; Wang QJ; Xia JC
    J Gastroenterol Hepatol; 2011 Mar; 26(3):544-9. PubMed ID: 21332550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PBK/TOPK expression correlates with mutant p53 and affects patients' prognosis and cell proliferation and viability in lung adenocarcinoma.
    Lei B; Qi W; Zhao Y; Li Y; Liu S; Xu X; Zhi C; Wan L; Shen H
    Hum Pathol; 2015 Feb; 46(2):217-24. PubMed ID: 25466965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the expression of agrin, a basement membrane heparan sulfate proteoglycan, in cholangiocarcinoma and hepatocellular carcinoma.
    Batmunkh E; Tátrai P; Szabó E; Lódi C; Holczbauer A; Páska C; Kupcsulik P; Kiss A; Schaff Z; Kovalszky I
    Hum Pathol; 2007 Oct; 38(10):1508-15. PubMed ID: 17640714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of cytokeratin 19 in human hepatocellular carcinoma cell lines.
    Wu F; Nishioka M; Fujita J; Murota M; Ohtsuki Y; Ishida T; Kuriyama S
    Int J Oncol; 2002 Jan; 20(1):31-7. PubMed ID: 11743639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Selective deposition of agrin in the microvasculature of hepatocellular carcinoma: aspects in pathogenesis and differential diagnosis].
    Tátrai P
    Magy Onkol; 2008 Dec; 52(4):379-83. PubMed ID: 19068466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hepatocellular carcinoma and cholangiocarcinoma--different prognosis, pathogenesis and therapy].
    Tischoff I; Tannapfel A
    Zentralbl Chir; 2007 Aug; 132(4):300-5. PubMed ID: 17724632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of c-erbB-2 proto-oncogene in extrahepatic cholangiocarcinoma and its clinical significance.
    Zheng J; Zhu YM
    Hepatobiliary Pancreat Dis Int; 2007 Aug; 6(4):412-5. PubMed ID: 17690040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Underexpressed microRNA-199b-5p targets hypoxia-inducible factor-1α in hepatocellular carcinoma and predicts prognosis of hepatocellular carcinoma patients.
    Wang C; Song B; Song W; Liu J; Sun A; Wu D; Yu H; Lian J; Chen L; Han J
    J Gastroenterol Hepatol; 2011 Nov; 26(11):1630-7. PubMed ID: 21557766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of insulin like-growth factor II messenger RNA binding protein-3 in diagnostic pathology.
    Findeis-Hosey JJ; Xu H
    Hum Pathol; 2011 Mar; 42(3):303-14. PubMed ID: 20970161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathologic significance and function of S-phase kinase-associated protein 2 overexpression in hepatocellular carcinoma.
    Zhang SH; Qian YM; Liu AW; Cai J; Zhao XL; Wei JJ; Zhu MH
    Hum Pathol; 2012 Jul; 43(7):1084-93. PubMed ID: 22204716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical roles of LGN/GPSM2 phosphorylation by PBK/TOPK in cell division of breast cancer cells.
    Fukukawa C; Ueda K; Nishidate T; Katagiri T; Nakamura Y
    Genes Chromosomes Cancer; 2010 Oct; 49(10):861-72. PubMed ID: 20589935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. cDNA arrays and immunohistochemistry identification of CD10/CALLA expression in hepatocellular carcinoma.
    Xiao SY; Wang HL; Hart J; Fleming D; Beard MR
    Am J Pathol; 2001 Oct; 159(4):1415-21. PubMed ID: 11583969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative immunohistochemical expression of p63 in human cholangiocarcinoma and hepatocellular carcinoma.
    Ramalho FS; Ramalho LN; Della Porta L; Zucoloto S
    J Gastroenterol Hepatol; 2006 Aug; 21(8):1276-80. PubMed ID: 16872309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fascin overexpression is involved in carcinogenesis and prognosis of human intrahepatic cholangiocarcinoma: immunohistochemical and molecular analysis.
    Iguchi T; Aishima S; Taketomi A; Nishihara Y; Fujita N; Sanefuji K; Sugimachi K; Yamashita Y; Maehara Y; Tsuneyoshi M
    Hum Pathol; 2009 Feb; 40(2):174-80. PubMed ID: 18835624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PBK/TOPK is a novel mitotic kinase which is upregulated in Burkitt's lymphoma and other highly proliferative malignant cells.
    Simons-Evelyn M; Bailey-Dell K; Toretsky JA; Ross DD; Fenton R; Kalvakolanu D; Rapoport AP
    Blood Cells Mol Dis; 2001; 27(5):825-9. PubMed ID: 11783945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.